New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
This approval reflects company’s unwavering commitment that the quality assurance
The exclusive hospital will help address health complexities concerning women and children, specializing in high-end obstetrics, comprehensive gynecological, neonatal & pediatric care
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Eugia Steriles receives EIR from USFDA for new injectable facility
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
Subscribe To Our Newsletter & Stay Updated
